Alliancebernstein L.P. Has $145.51 Million Stock Position in Repligen Co. (NASDAQ:RGEN)

Alliancebernstein L.P. grew its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 23.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,010,896 shares of the biotechnology company's stock after buying an additional 191,439 shares during the quarter. Alliancebernstein L.P. owned 1.80% of Repligen worth $145,508,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in RGEN. Vanguard Group Inc. raised its stake in shares of Repligen by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after purchasing an additional 56,723 shares during the period. Conestoga Capital Advisors LLC grew its stake in shares of Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock valued at $136,395,000 after buying an additional 6,872 shares in the last quarter. DF Dent & Co. Inc. raised its position in Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock worth $87,852,000 after acquiring an additional 139,615 shares in the last quarter. New York State Common Retirement Fund grew its position in shares of Repligen by 2.5% in the 4th quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company's stock valued at $83,693,000 after acquiring an additional 14,398 shares during the period. Finally, Stephens Investment Management Group LLC raised its holdings in shares of Repligen by 7.4% in the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock valued at $77,267,000 after purchasing an additional 37,057 shares during the period. Institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on RGEN. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. Canaccord Genuity Group raised their price target on Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a report on Friday, February 21st. Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective on the stock. TD Cowen began coverage on shares of Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 target price for the company. Finally, Royal Bank of Canada upped their price target on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research note on Friday, February 21st. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $178.64.

Repligen Price Performance

RGEN stock traded down $9.76 during trading on Friday, reaching $111.94. 1,826,070 shares of the company were exchanged, compared to its average volume of 686,321. Repligen Co. has a twelve month low of $106.78 and a twelve month high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company has a market capitalization of $6.29 billion, a price-to-earnings ratio of -219.49, a P/E/G ratio of 4.54 and a beta of 1.27. The company has a 50-day moving average of $150.03 and a two-hundred day moving average of $147.58.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, equities analysts predict that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Margaret Pax purchased 250 shares of the stock in a transaction on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is owned by corporate insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.